Clinical trials
catalyst calendar across sponsors →Studies where HURA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 1 expanded access · 2 with posted results
Held by 8 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, AQR CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, Qube Research & Technologies Ltd, +3 more) · FINRA short interest 31.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell CarcinomaNCT06947928Objective response rate (ORR)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: IFx-Hu2.0, Placebo, Pembrolizumab | Advanced Or Metastatic Merkel Cell Carcinoma | 118 | 2027-03-31 | in 224 d | 2026-04-17 |
| IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)NCT06940440SafetyOpen-label · Treatment | Phase 1 | Recruiting | Drug: IFx-Hu2.0, Pembrolizumab | Advanced Or Metastatic Merkel Cell Carcinoma | 9 | 2026-05-31 | — | 2025-10-15 |
| Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin CancersNCT04160065Number of Grade 3-5, Treatment-Related Adverse Events per CTCAE 5.0Open-label · Treatment | Phase 1 | Completed | Biological: IFx-Hu2.0 | Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers | 23 | 2023-10-19actual | — | 2024-09-23 |
| IFx-Hu2.0 for the Treatment of Patients With Skin CancerNCT04925713results2024-08-02Rate of Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: IFx-Hu2.0 | Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | 5 | 2021-10-07actual | — | 2024-08-02 |
| pDNA Intralesional Cancer Vaccine for Cutaneous MelanomaNCT03655756results2022-08-08Number of Participants With Serious Adverse Events (SAEs) and/or Dose Limiting Toxicities (DLTs)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Early Phase 1 | Completed | Biological: IFx-Hu2.0 | Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV | 7 | 2020-07-10actual | — | 2022-08-08 |
| IFx-Hu2.0 Expanded Access ProgramNCT04853602expanded access | — | Available | Biological: IFx-Hu2.0 | Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma | — | — | — | 2024-08-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19